Vorinostat

Drug Profile

Vorinostat

Alternative Names: L-001079038; MK 0683; SAHA; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Zolinza

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Columbia University; Memorial Sloan-Kettering Cancer Center
  • Developer Banyu; Columbia University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; Roswell Park Cancer Institute; Stanford University; University of North Carolina at Chapel Hill; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Multiple myeloma; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma
  • Phase II Acute myeloid leukaemia; B cell lymphoma; Breast cancer; Glioma; HIV-1 infections; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • No development reported Brain metastases; Colorectal cancer; Glioblastoma; Hodgkin's disease
  • Discontinued Gynaecological cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Sickle cell anaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Brain metastases in USA (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Recurrent) in USA (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hodgkin's-disease(Combination therapy, Second-line therapy or greater) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top